Ethical review in the pharmaceutical industry

Area of Science:

• Clinical Pharmacology
• Bioethics
• Pharmaceutical Research

Background:

• Ethical review is standard for clinical research.
• Pharmaceutical industry clinical pharmacology studies may lack independent ethical oversight.
• Ethical review protects human subjects and corporate integrity.

Purpose of the Study:

• To advocate for mandatory ethical review of clinical pharmacology studies within the pharmaceutical industry.
• To address concerns regarding the impact of ethical review on research timelines.
• To emphasize the importance of perceived independence and competence in ethical review committees.

Main Methods:

• Review of ethical principles in clinical research.
• Analysis of the role of independent ethical review boards (IRBs) in industry-sponsored studies.
• Case experience from a pharmaceutical company's implementation of ethical review.

Main Results:

• Independent ethical review is justifiable and necessary for pharmaceutical industry clinical pharmacology studies.
• Implementation of independent ethical review did not significantly impede research progress in one company's experience.
• The perceived independence and competence of ethical review committees are crucial for their acceptance and effectiveness.

Conclusions:

• Clinical pharmacology studies in the pharmaceutical industry should be subject to independent ethical review.
• Ethical review serves to protect volunteer subjects and mitigate corporate vulnerability.
• Independent ethical review can be integrated into industry research without compromising efficiency, provided committees are competent and independent.